Trending Now
Cancer is Still the Real Global Health Crisis… Four Stocks with...
While Covid-19 continues to steal the headlines, the multi-century pandemic known as Cancer still deserves the brunt of our attention. And it’s getting it....
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Sezzle (NASDAQ: SEZL) Shares Surge on Robust Q1 Earnings and Upgraded...
Sezzle Inc. (NASDAQ:SEZL) saw its stock price increase today primarily due to its strong first-quarter financial performance for 2024. The company reported...
MAKE IT MODERN
LATEST REVIEWS
Markets could rebound today: SPY September 30, 300 Calls
This morning's scan is easier than yesterday's. Usually, Mondays are some of the trickiest days over the years. There is mixed news...
MAKE IT MODERN
PERFORMANCE TRAINING
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) Finalizes RESOLVE-1 Third Phase Lenabasum Study In Systemic Sclerosis
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) has announced that the last subject in its RESOLVE-1 third phase lenabasum study for systemic sclerosis treatment has competed...
Sorrento Therapeutics Inc (NASDAQ: SRNE) Recently Issued an Update of Its STL 919 Study
Sorrento Therapeutics Inc (NASDAQ: SRNE) recently updated its recent study to its shareholders. The company announced that it recruited fit volunteers. Moreover, the study...
Alector Inc (NASDAQ: ALEC) Announced the Results of the Phase-2 INFRONT-2 Open-Label Study of...
Aelector Inc (NASDAQ: ALEC) is a clinical biotech corporation that recently announced promising results from its Phase-2 INFRONT-2 trial of ALOO1. The Alzheimer's Association International...
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Sanofi Announce Positive Pivotal Results of Second...
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Sanofi have announced encouraging pivotal findings from the second phase three study, PRIME, evaluating Dupixent in adults with...
Harrow: Strong Second Quarter Growth Highlights Future Potential
Harrow (Nasdaq: HROW), a frontrunner in the North American eyecare pharmaceutical landscape, has recently unveiled its financial achievements for the second quarter...
MAKE IT MODERN
